Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) AI Stock Analysis

• Market Cap: HK$1.17B
• Dividend Yield: 2.93%
• Average Volume (3M): 134.61K
• Price to Earnings (P/E): 5.8
• Beta (1Y): 0.38
• Revenue Growth: 2.82%
• EPS Growth: 21.63%
• Country: HK
• Employees: 745
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.36
• Shares Outstanding: 172,500,000
• 10 Day Avg. Volume: 68,800
• 30 Day Avg. Volume: 134,606
• PEG Ratio: 0.06
• Price to Book (P/B): 0.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 2.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 81 Outperform
• Price Target: HK$2.50 ▲(19.62%Upside)

The strong financial performance and attractive valuation are the most significant factors contributing to the stock's high score. While technical analysis shows a bullish trend, the overbought RSI suggests caution. The absence of earnings call data and corporate events did not impact the score.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) is a pharmaceutical company based in China, primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company focuses on a range of products including traditional Chinese medicine, chemical pharmaceuticals, and biological drugs. It is committed to innovation in healthcare solutions and the advancement of medicine to improve patient outcomes.

How the Company Makes Money

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. generates revenue through the sale of its pharmaceutical products, which include traditional Chinese medicine and modern pharmaceuticals. The company leverages its research and development capabilities to create proprietary drugs and collaborates with healthcare institutions for clinical trials and product distribution. Key revenue streams include domestic and international sales of its medical products, as well as potential strategic partnerships with other pharmaceutical companies for joint ventures and product licensing agreements.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Financial Statement Overview

Summary

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has demonstrated strong financial performance with consistent revenue and profit growth, robust margins, and a stable financial structure. The company maintains a low debt-to-equity ratio and a solid equity base, although there is a noted decrease in free cash flow growth.

Income Statement

The company has demonstrated consistent revenue growth with a revenue growth rate of 4.7% in 2024, while maintaining strong profitability margins. Gross profit margin stands at 77.8% and net profit margin at 20.9% in 2024, reflecting efficient cost management and solid earnings. The EBIT margin of 23.7% and EBITDA margin of 26.8% further highlight strong operational performance.

Balance Sheet

The balance sheet is robust with a low debt-to-equity ratio of 0.04, indicating minimal leverage and financial risk. The company has a healthy equity ratio of 64.4%, showcasing strong equity financing. Return on equity is solid at 11.3%, indicating effective utilization of shareholder funds. The financial stability is bolstered by a significant cash reserve.

Cash Flow

The company exhibits strong cash flow generation with a free cash flow of 208.6 million. However, the free cash flow decreased by 26.6% from the previous year due to a reduction in operating cash flow. The operating cash flow to net income ratio of 1.19 indicates robust cash conversion, while the free cash flow to net income ratio of 1.13 underscores effective capital expenditure management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	839.00M	881.16M	841.54M	841.59M	705.46M	622.25M
Gross Profit	633.10M	685.25M	584.05M	648.03M	580.00M	530.74M
EBITDA	232.72M	236.33M	226.39M	231.43M	206.50M	172.92M
Net Income	171.64M	184.25M	148.21M	193.56M	143.28M	126.56M
Balance Sheet
Total Assets	2.36B	2.53B	2.32B	2.37B	2.07B	1.80B
Cash, Cash Equivalents and Short-Term Investments	645.67M	539.03M	655.59M	1.03B	262.25M	242.94M
Total Debt	83.75M	72.40M	80.40M	400.00K	400.00K	400.00K
Total Liabilities	780.16M	901.49M	838.44M	760.54M	618.56M	459.02M
Stockholders Equity	1.58B	1.63B	1.48B	1.61B	1.45B	1.35B
Cash Flow
Free Cash Flow	0.00	208.63M	284.11M	192.68M	122.25M	52.46M
Operating Cash Flow	0.00	219.65M	315.95M	203.99M	215.09M	151.23M
Investing Cash Flow	0.00	-310.93M	109.04M	-117.97M	-160.61M	-244.85M
Financing Cash Flow	0.00	-25.01M	-186.45M	-27.71M	-25.20M	-17.75M

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8049, the sentiment is Positive. The current price of 2.09 is below the 20-day moving average (MA) of 2.10, above the 50-day MA of 1.90, and above the 200-day MA of 1.44, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 61.77 is Neutral, neither overbought nor oversold. The STOCH value of 11.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8049.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8049	81 Outperform	HK$1.17B	5.83		2.93%	2.82%	21.63%
2161	79 Outperform	HK$2.71B	13.70	19.22%	2.89%	18.06%	80.57%
2348	73 Outperform	HK$1.86B	3.05	18.33%	4.84%	-9.95%	67.56%
3737	70 Outperform	HK$745.36M	7.21	8.81%	5.68%	5.79%	-43.49%
0950	67 Neutral	HK$847.92M	9.11	5.04%	3.55%	32.95%	456.69%
Sector *	60 Neutral	HK$15.31B	5.72	-7.43%	4.61%	11.60%	-21.06%
1652	49 Neutral	HK$286.74M	―	-40.39%	―	-43.73%	-434.56%